Rossari Biotech Limited (ROSSARI) — Board Meeting

1 Board Meeting 🟡 Notable Neutral 📄 PDF

📢 Key Event
Board re-appoints Esha Padmanabhan Achan as Independent Director and grants 830,050 stock options under ESOP 2019.

🔄 What Changed
Re-appointment of Ms. Esha Padmanabhan Achan as Non-Executive Independent Director for a second term; Grant of 830,050 stock options under ESOP 2019.

🔮 What's Next
Re-appointment effective October 21, 2026 to October 20, 2029, subject to shareholder approval; Options vest over four years with 20% annually, exercisable within five years of vesting.

💡 Investor Takeaway
The re-appointment strengthens board continuity, while the new stock options may dilute shares and signal confidence in future performance.

Rossari Biotech announced the outcome of its May 27, 2026 board meeting, approving the re-appointment of Ms. Esha Padmanabhan Achan as a Non-Executive Independent Director for a second term from October 21, 2026 to October 20, 2029, pending shareholder approval, and granting 830,050 stock options under the 2019 Employee Stock Option Plan with an exercise price of Rs. 537 per option, vesting over four years.

2 Board Meeting 🟡 Notable Neutral 📄 PDF

📢 Key Event
Board approves re-appointment of Esha Padmanabhan Achan and ESOP 2019 grant of 830,050 options.

🔄 What Changed
Re-appointment of Ms. Esha Padmanabhan Achan as Non-Executive Independent Director for a second term; grant of 830,050 stock options under ESOP 2019.

🔮 What's Next
Re-appointment effective October 21, 2026 to October 20, 2029, pending shareholder approval.

💡 Investor Takeaway
The re-appointment strengthens board continuity, while the ESOP grant signals confidence in future performance but may dilute share value upon exercise.

Rossari Biotech announced the re-appointment of Ms. Esha Padmanabhan Achan as a Non-Executive Independent Director for a second term from October 21, 2026 to October 20, 2029, subject to shareholder approval, and granted 830,050 stock options under its 2019 Employee Stock Option Plan with an exercise price of Rs. 537 per option, vesting over four years.

3 Board Meeting 🟡 Notable Neutral 📄 PDF

📢 Key Event
Board re-appointed Ms. Esha Padmanabhan Achan as Independent Director and granted 830,050 stock options.

🔄 What Changed
Re-appointment of Ms. Esha Padmanabhan Achan as Non-Executive Independent Director; Grant of 830,050 stock options under ESOP 2019.

🔮 What's Next
Re-appointment effective October 21, 2026 to October 20, 2029; Options vesting over four years with 20% annually after years 1-3 and 40% in year 4.

💡 Investor Takeaway
The re-appointment strengthens governance continuity, while the stock option grant may dilute existing shares and signal confidence in future performance.

Rossari Biotech announced the outcome of its May 27, 2026 board meeting, approving the re-appointment of Ms. Esha Padmanabhan Achan as a Non-Executive Independent Director for a three-year term starting October 21, 2026, and granting 830,050 stock options under the 2019 Employee Stock Option Plan, with an exercise price of Rs. 537 per option and a four-year vesting schedule.

📊 Stock Analysis — ROSSARI ✨ Ask AI About This